相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database
Ann S. LaCasce et al.
BLOOD (2012)
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Patricia Perez-Galan et al.
BLOOD (2011)
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Jonathan W. Friedberg et al.
BLOOD (2011)
Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation
Lihua E. Budde et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Jia Ruan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Christian H. Geisler et al.
BLOOD (2010)
Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma
Veronica Fernandez et al.
CANCER RESEARCH (2010)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Constantine S. Tam et al.
BLOOD (2009)
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Thomas M. Habermann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Michael Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Peter Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group
Stephen M. Ansell et al.
CANCER (2008)
Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
Elena Hartmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
[18F] fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma
Saar Gill et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Central nervous system involvement in mantle cell lymphoma
A. Ferrer et al.
ANNALS OF ONCOLOGY (2008)
Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics
Pedro Jares et al.
NATURE REVIEWS CANCER (2007)
Leukemic involvement is a common feature in mantle cell lymphoma
Ana Ferrer et al.
CANCER (2007)
The cellular origin of mantle cell lymphoma
Francesco Bertoni et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network
B. S. Kahl et al.
ANNALS OF ONCOLOGY (2006)
Update on the molecular biology of mantle cell lymphoma
F Bertoni et al.
HEMATOLOGICAL ONCOLOGY (2006)
Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL):: a clinicopathological study from the European MCL Network
M Tiemann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma:: Results of a prospective randomized trial of the German low grade lymphoma study group (GLSG)
G Lenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma
MB Maris et al.
BLOOD (2004)
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
JE Romaguera et al.
CANCER (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald et al.
CANCER CELL (2003)
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival
OM Howard et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Blastic variant of mantle cell lymphoma:: a rare but highly aggressive subtype
M Bernard et al.
LEUKEMIA (2001)
Phosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma
BJ Cohen et al.
LEUKEMIA & LYMPHOMA (2001)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
JM Foran et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)